Effect of gemcitabine on the tolerance of the lung to single-dose irradiation in C3H mice

Radiation Research

Volumn 151, Issue 6, 1999, Pages 747-749

  Grégoire, Vincent ^a   Cvilic, Sophie ^a   Beauduin, Marc ^b   De Coster, Blanche ^a   Gueulette, John ^a   Octave Prignot, Michelle ^a   Scalliet, Pierre ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Hospital de Jolimont   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; IRRADIATION; LETHAL DOSE; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; THORAX; TREATMENT OUTCOME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, RADIATION; LUNG; MALE; MICE; MICE, INBRED C3H; RADIATION TOLERANCE;

ANIMALIA;

EID: 0345104352     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.2307/3580214     Document Type: Article

References (15)

1. W. Plunkett and V. Gandhi, Nucleoside analogs: Cellular pharmacology, mechanisms of action, and strategies for combination therapy. In Nucleoside Analogs in Cancer Therapy (B. D. Cheson, M. J. Keating and W. Plunkett, Eds.), pp. 1-36. Marcel Dekker, New York, 1997.
2. H. J. Guchelaar, D. J. Richel and A. van Knapen, Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat. Rev. 22, 15-31 (1996).
3. V. Grégoire and W. N. Hittelman, Nucleoside analogs as radiosensitizing agents. In Nucleoside Analogs in Cancer Therapy (B. D. Cheson, M. J. Keating and W. Plunkett, Eds.), pp. 315-358. Marcel Dekker, New York, 1997.
4. J. F. Rosier, M. Beauduin, M. Bruniaux, B. De Coster, M. De Bast, P. Scalliet and V. Grégoire, The role of gemcitabine-induced cell cycle synchronization in radiosensitization of a SCC61 human head and neck squamous cell carcinoma cell (HNSCC) line. Eur. J. Cancer 33 (Suppl. 8), S23 (1997). [Abstract]
5. J. F. Rosier, L. Michaux, J. M. Libouton, C. Verellen, P. Scalliet and V. Grégoire, Repair inhibition of radiation-induced chromosome aberrations but not DNA DSBs is involved in gemcitabine's (dFdC) radio-enhancement. Radiother. Oncol. 48 (Suppl. 1), S184 (1998). [Abstract]
6. V. Grégoire, M. Beauduin, J. F. Rosier, B. De Coster, M. Bruniaux, M. Octave-Prignot and P. Scalliet, Kinetics of mouse jejunum radiosensitization by 2′,2′-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells. Br. J. Cancer 76, 1315-1321 (1997).
7. D. S. Shewach, T. M. Hahn, E. Chang, L. W. Hertel and T. S. Lawrence, Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 54, 3218-3223 (1994).
8. V. Grégoire, M. Beauduin, M. Bruniaux, B. De Coster, M. Octave-Prignot and P. Scalliet, Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed field gel electrophoresis. Int. J. Radiat. Biol. 73, 511-520 (1998).
9. T. S. Lawrence, E. Y. Chang, T. M. Hahn and D. S. Shewach, Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (gemcitabine). Clin. Cancer Res. 3, 777-782 (1997).
10. V. Grégoire, M. Beauduin, J. Gueulette, B. M. De Coster, M. Octave-Prignot, S. Vynckier and A. Wambersie, Radiobiological intercomparison of p(45)+Be and p(65)+Be neutron beams for lung tolerance in mice after single and fractionated irradiation. Radiat. Res. 133, 27-32 (1993).
11. E. H. Porter, The statistics of dose/cure relationships for irradiated tumours. Part I. Br. J. Radiat. 53, 210-227 (1980).
12. T. L. Phillips and G. Ross, Time-dose relationships in the mouse esophagus. Radiology 113, 435-440 (1974).
13. G. Veerman, V. W. Ruiz van Haperen, J. B. Vermorken, P. Noordhuid, B. J. Braakhuis, H. H. Pinedo and G. J. Peters, Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother. Pharmacol. 38, 335-342 (1996).
14. G. J. Peters and S. P. Ackland, New antimetabolites in preclinical and clinical development. Exp. Opin. Invest. Drugs 5, 637-379 (1996).
15. V. Heinemann, Y-Z. Xu, S. Chubb, A. Sen, L. W. Hertel, G. B. Grindey and W. Plunkett, Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation. Cancer Res. 52, 533-539 (1992).